HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study.
Antiviral treatment
Dried blood spot
HIV
Hepatitis C
People who use drugs
Point-of-care
Retention in care
Screening
Journal
Infectious diseases of poverty
ISSN: 2049-9957
Titre abrégé: Infect Dis Poverty
Pays: England
ID NLM: 101606645
Informations de publication
Date de publication:
19 Aug 2021
19 Aug 2021
Historique:
received:
10
06
2021
accepted:
08
08
2021
entrez:
20
8
2021
pubmed:
21
8
2021
medline:
26
11
2021
Statut:
epublish
Résumé
The burden of human immunodeficiency virus (HIV) infection in people who use drugs (PWUD) is significant. We aimed to screen HIV infection among PWUD and describe their retention in HIV care. Besides, we also screen for hepatitis C virus (HCV) infection among HIV-seropositive PWUD and describe their linkage to care. We conducted a prospective study in 529 PWUD who visited the "Cañada Real Galiana" (Madrid, Spain). The study period was from June 1, 2017, to May 31, 2018. HIV diagnosis was performed with a rapid antibody screening test at the point-of-care (POC) and HCV diagnosis with immunoassay and PCR tests on dried blood spot (DBS) in a central laboratory. Positive PWUD were referred to the hospital. We used the Chi-square or Fisher's exact tests, as appropriate, to compare rates between groups. Thirty-five (6.6%) participants were positive HIV antibodies, but 34 reported previous HIV diagnoses, and 27 (76%) had prior antiretroviral therapy. Among patients with a positive HIV antibody test, we also found a higher prevalence of homeless (P < 0.001) and injection drug use (PWID) (P < 0.001), and more decades of drug use (P = 0.002). All participants received HIV test results at the POC. Of the 35 HIV positives, 28 (80%) were retained in HIV medical care at the end of the HIV screening study (2018), and only 22 (62.9%) at the end of 2020. Moreover, 12/35 (34.3%) were positive for the HCV RNA test. Of the latter, 10/12 (83.3%) were contacted to deliver the HCV results test (delivery time of 19 days), 5/12 (41.7%) had an appointment and were attended at the hospital and started HCV therapy, and only 4/12 (33.3%) cleared HCV. We found almost no new HIV-infected PWUD, but their cascade of HIV care was low and remains a challenge in this population at risk. The high frequency of active hepatitis C in HIV-infected PWUD reflects the need for HCV screening and reinforcing the link to care.
Sections du résumé
BACKGROUND
BACKGROUND
The burden of human immunodeficiency virus (HIV) infection in people who use drugs (PWUD) is significant. We aimed to screen HIV infection among PWUD and describe their retention in HIV care. Besides, we also screen for hepatitis C virus (HCV) infection among HIV-seropositive PWUD and describe their linkage to care.
METHODS
METHODS
We conducted a prospective study in 529 PWUD who visited the "Cañada Real Galiana" (Madrid, Spain). The study period was from June 1, 2017, to May 31, 2018. HIV diagnosis was performed with a rapid antibody screening test at the point-of-care (POC) and HCV diagnosis with immunoassay and PCR tests on dried blood spot (DBS) in a central laboratory. Positive PWUD were referred to the hospital. We used the Chi-square or Fisher's exact tests, as appropriate, to compare rates between groups.
RESULTS
RESULTS
Thirty-five (6.6%) participants were positive HIV antibodies, but 34 reported previous HIV diagnoses, and 27 (76%) had prior antiretroviral therapy. Among patients with a positive HIV antibody test, we also found a higher prevalence of homeless (P < 0.001) and injection drug use (PWID) (P < 0.001), and more decades of drug use (P = 0.002). All participants received HIV test results at the POC. Of the 35 HIV positives, 28 (80%) were retained in HIV medical care at the end of the HIV screening study (2018), and only 22 (62.9%) at the end of 2020. Moreover, 12/35 (34.3%) were positive for the HCV RNA test. Of the latter, 10/12 (83.3%) were contacted to deliver the HCV results test (delivery time of 19 days), 5/12 (41.7%) had an appointment and were attended at the hospital and started HCV therapy, and only 4/12 (33.3%) cleared HCV.
CONCLUSIONS
CONCLUSIONS
We found almost no new HIV-infected PWUD, but their cascade of HIV care was low and remains a challenge in this population at risk. The high frequency of active hepatitis C in HIV-infected PWUD reflects the need for HCV screening and reinforcing the link to care.
Identifiants
pubmed: 34412695
doi: 10.1186/s40249-021-00894-5
pii: 10.1186/s40249-021-00894-5
pmc: PMC8375145
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111Subventions
Organisme : Merck Sharp and Dohme
ID : MISP IIS#54846
Organisme : Instituto de Salud Carlos III
ID : PI20CIII/00004
Organisme : Instituto de Salud Carlos III
ID : RD16CIII/0002/0002
Informations de copyright
© 2021. The Author(s).
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Int J Epidemiol. 2014 Feb;43(1):235-48
pubmed: 24374889
AIDS Behav. 2013 Nov;17(9):2878-92
pubmed: 23975473
Emerg Infect Dis. 2018 Mar;24(3):413-416
pubmed: 29460740
PLoS One. 2013 Dec 16;8(12):e81715
pubmed: 24358123
Sex Transm Dis. 2018 Jul;45(7):494-504
pubmed: 29465661
Hepatol Commun. 2020 Mar 03;4(5):646-656
pubmed: 32363316
HIV Med. 2017 Aug;18(7):490-499
pubmed: 28117527
Open AIDS J. 2013 Aug 13;7:17-41
pubmed: 24133558
AIDS Patient Care STDS. 2015 May;29(5):279-87
pubmed: 25826007
PLoS One. 2014 Sep 30;9(9):e108615
pubmed: 25268903
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
PLoS One. 2017 May 17;12(5):e0177402
pubmed: 28520749
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):695
pubmed: 29143615
Int J Drug Policy. 2021 Jun;92:103134
pubmed: 33517130
Harm Reduct J. 2021 Jan 6;18(1):2
pubmed: 33407562
Drug Alcohol Depend. 2021 Apr 1;221:108560
pubmed: 33607498
BMC Public Health. 2015 Feb 07;15:106
pubmed: 25884182
Epidemiol Infect. 2004 Aug;132(4):699-708
pubmed: 15310172
AIDS Behav. 2018 Mar;22(3):752-764
pubmed: 27990582
Expert Rev Anti Infect Ther. 2019 May;17(5):341-347
pubmed: 30950298
AIDS Behav. 2018 Mar;22(3):742-751
pubmed: 28612213
Sci Rep. 2018 Jan 30;8(1):1858
pubmed: 29382904
PLoS One. 2014 Jul 02;9(7):e101554
pubmed: 24988388
HIV Clin Trials. 2009 Sep-Oct;10(5):299-305
pubmed: 19906622
Cochrane Database Syst Rev. 2017 Sep 18;9:CD012021
pubmed: 28922449
Lancet. 2016 Sep 17;388(10050):1228-48
pubmed: 27427455
PLoS One. 2014 Dec 26;9(12):e115277
pubmed: 25541682
Lancet HIV. 2018 Jun;5(6):e269-e270
pubmed: 29893238
Lancet. 2010 Jul 24;376(9737):268-84
pubmed: 20650523
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
Curr Opin Infect Dis. 2015 Feb;28(1):10-6
pubmed: 25490106
Pathogens. 2020 May 31;9(6):
pubmed: 32486342
Public Health Rep. 2002;117 Suppl 1:S135-45
pubmed: 12435837
Lancet. 2018 Jan 20;391(10117):241-250
pubmed: 29137869